Methods comprising apoptosis inhibitors for the generation of transgenic pigs |
 |
|
|
||||||||||||||||||||||||||||||||||||||||||
| Title: | Method for increasing neutrophil populations using in vitro-derived human neutrophil precursor cells |
| Inventors: | Bender, James G.; Lindenhurst, IL, USA Maples, Phillip B.; Waukegan, IL, USA Smith, Stephen; Arlington Heights, IL, USA Unverzagt, Kristen L.; Palatine, IL, USA Van Epps, Dennis E.; Cary, IL, USA |
| Summary: | Described herein is a therapeutic method of correcting an abnormally low level of neutrophils, via the administration of a suspension of human neutrophil precursor cells wherein the cellular component is comprised of approximately 16% of CD15+CD11b- human neutrophil precursor cells and less than approximately 5% of CD34+ colony forming units such that approximately 60% or more of the precursor cells are myeloblasts and promyelocytes. Specific examples are included for the treatment of neutropenia in a human patient. |
| Abstract: | A suspension comprising human neutrophil precursor cells, wherein the cellular component is comprised of at least about 16% human myeloblasts and promyeclocytes, which have been derived from neutrophis progenitor cells obtained from peripheral blood, bone marrow or cord blood, and less than about 5% colony forming units (CFU) of at least about 50 cells is provided. An alternative suspension comprising human neutrophil precursor cells, wherein the cellular component is comprised of at least about 16% CD15+CD11b- cells and less than about 5% colony forming units (CFU) of at least about 50 cells also is provided, wherein at least about 60% of the CD15+CD11b- cells are myeloblasts and promyelocytes. The suspensions of the invention are useful in methods for increasing neutrophil populations in a patient having a reduced populations of neutrophils. |
| US Patent Website: | Click Here for Full Text of Patent |
| Title Number: | US5888499 |
| Application Number: | US1995000481894 |
| Date Filed: | 07/06/1995 |
| Date Published: | 30/03/1999 |
| Assignee: | Nexell Therapeutics Inc., Irvine, CA, USA |